Results 201 to 210 of about 165,122 (254)
Some of the next articles are maybe not open access.
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
European Atherosclerosis Journal, 2022The causal role of low-density lipoprotein cholesterol LDL-C in atherosclerotic-related cardiovascular disease (ASCVD) has been undoubtedly established over the last decades, and lowering plasma LDL-C levels represents the main approach to reduce the risk of cardiovascular (CV) events.
Ballantyne, Christie M. +1 more
openaire +1 more source
Rationale for cholesterol lowering
The American Journal of Medicine, 1989Evidence from research in five areas (epidemiology, experimental pathology, clinical medicine, clinical genetics, and clinical trials) provides the basis for current strategies for lowering cholesterol levels. Current interest in this field has been intensified by new information on the mechanisms of pathogenicity of cholesterol-rich plasma ...
openaire +2 more sources
Cholesterol lowering in atherosclerosis
The American Journal of Cardiology, 2000Lipid-lowering with statins reduces disease progression, prevents myocardial infarction and other hard end points, and prolongs survival. Data from large-scale trials with these agents further show that lowering low-density lipoprotein (LDL) cholesterol in patients with coronary artery disease reduces the incidence of cardiovascular events and that the
openaire +2 more sources
1972
Discussions of the question before this panel frequently take a disturbingly illogical course. I refer to the following common argument: the cholesterol hypothesis, we are told, has been before us for decades, and the possibility of prevention has been under study in man for twelve or fifteen years.
openaire +2 more sources
Discussions of the question before this panel frequently take a disturbingly illogical course. I refer to the following common argument: the cholesterol hypothesis, we are told, has been before us for decades, and the possibility of prevention has been under study in man for twelve or fifteen years.
openaire +2 more sources
Pharmacogenomics of cholesterol-lowering therapy
Vascular Pharmacology, 2006The prevention of cardiovascular disease is critically dependent on lipid-lowering therapy, including 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), cholesterol absorption inhibitors, bile acid resins, fibrates, and nicotinic acid. Although these drugs are generally well tolerated, severe adverse effects can occur
Gerd, Schmitz, Thomas, Langmann
openaire +2 more sources
Ezetimibe: cholesterol lowering and beyond
Expert Review of Cardiovascular Therapy, 2008Ezetimibe is a cholesterol absorption inhibitor that blocks the intestinal absorption of both biliary and dietary cholesterol. It appears to exert its effect by blocking intestinal sterol transporters, specifically Niemann-Pick C1-like 1 proteins, thereby inhibiting the intestinal absorption of cholesterol, phytosterols and certain oxysterols ...
Harold E, Bays +3 more
openaire +2 more sources
Archives of Internal Medicine, 1995
To evaluate the efficacy of the high-risk approach and the population approach for cholesterol lowering, large trials of dietary intervention (n > or = 150) and smaller trials of angiographic assessment of the impact of diet on coronary disease were reviewed.
openaire +2 more sources
To evaluate the efficacy of the high-risk approach and the population approach for cholesterol lowering, large trials of dietary intervention (n > or = 150) and smaller trials of angiographic assessment of the impact of diet on coronary disease were reviewed.
openaire +2 more sources
Pleiotropic Effects and Cholesterol-Lowering Therapy
Cardiology, 2008HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, or ‘statins’, have revolutionized the management of patients with atherosclerotic vascular disease. Following 2 large acute coronary syndrome trials, additional clinical benefit outside their effect of low-density lipoprotein (LDL) lowering was proposed.
Shaw, Steven M. +3 more
openaire +2 more sources
Cholesterol lowering and endothelial function
The American Journal of Medicine, 1999The pathophysiology of the association between cholesterol and atherosclerosis has been thought to involve the deposition, modification, and cellular uptake of cholesterol. We now believe that the process begins with vascular injury and involves inflammation and vessel remodeling.
openaire +2 more sources
Cholesterol Lowering and Ezetimibe
New England Journal of Medicine, 2008In this issue of the Journal, we publish the results of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial,1 which addresses the question of whether additional lowering of low-density lipoprotein (LDL) cholesterol with ezetimibe beyond the level achieved with simvastatin beneficially affects the ...
Jeffrey M. Drazen +3 more
openaire +1 more source